These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11434621)

  • 1. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C.
    Caballero T; Pérez-Milena A; Masseroli M; O'Valle F; Salmerón FJ; Del Moral RM; Sánchez-Salgado G
    J Hepatol; 2001 May; 34(5):740-7. PubMed ID: 11434621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method.
    Duchatelle V; Marcellin P; Giostra E; Bregeaud L; Pouteau M; Boyer N; Auperin A; Guerret S; Erlinger S; Henin D; Degott C
    J Hepatol; 1998 Jul; 29(1):20-8. PubMed ID: 9696488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
    Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
    Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
    Mitsuda A; Suou T; Ikuta Y; Kawasaki H
    J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon.
    Boldorini R; Viganò P; Monga G; Nebuloni M; Cargnel A; Gubertini G; Migliaretti G; Costanzi G
    J Clin Pathol; 1997 Sep; 50(9):735-40. PubMed ID: 9389973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Various scoring systems evaluating histologic features of chronic hepatitis C treated with interferon.
    Ikawa H; Hayashi Y; Ninomiya T; Yano Y; Nakaji M; Nagano H; Seo Y; Kumon Y; Yoon S; Kasuga M; Itoh H; Ohbayashi C
    Hum Pathol; 2001 Sep; 32(9):910-7. PubMed ID: 11567219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
    Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
    Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
    Bruno S; Battezzati PM; Bellati G; Manzin A; Maggioni M; Crosignani A; Borzio M; Solforosi L; Morabito A; Ideo G; Podda M
    J Hepatol; 2001 May; 34(5):748-55. PubMed ID: 11434622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
    Cammà C; Di Bona D; Schepis F; Heathcote EJ; Zeuzem S; Pockros PJ; Marcellin P; Balart L; Alberti A; Craxì A
    Hepatology; 2004 Feb; 39(2):333-42. PubMed ID: 14767986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
    Wong JB; Bennett WG; Koff RS; Pauker SG
    JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
    Bajaj JS; Molina E; Regev A; Schiff ER; Jeffers LJ
    Gastrointest Endosc; 2003 Sep; 58(3):380-3. PubMed ID: 14528212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment.
    Jármay K; Gallai M; Karácsony G; Ozsvár Z; Schaff Z; Lonovics J; Kovalszky I
    J Hepatol; 2000 Jun; 32(6):993-1002. PubMed ID: 10898320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.